Pembrolizumab: effective immunotherapy for advanced head and neck cancer


An immunotherapy drug proves to be more effective than extreme chemotherapy in some patients.
Pembrolizumab kept head and neck cancers under control for an average of two years.
One in four patients with advanced head and neck cancer responded to the drug.
Does not kill cancer cells itself but instead stimulates the body's immune system to attack them.
Around 85% of people with advanced or relapsed head and neck cancer would be eligible for this.
Far fewer side effects, improves quality of life and doesn't damage kidneys, hands and feet.
In the US and the EU, pembrolizumab has been approved, could be approved for use in UK soon.
Research by Royal Marsden NHS Foundation Trust, published in the Lancet.

Needs to identify those who will respond to treatment before starting immunotherapy

Mentioned in this article:

Resource Institute of Cancer Research

Resource Kevin Harrington - Consultant Clinical Oncologist and Professor (BSc, MBBS, MRCP, FRCR, FRCP, PhD, DIC), specializes in Biological Cancer Therapies, head and neck cancer, immunotherapy.

Resource National Institute for Health and Care Excellence (NICE) - This institution provides national guidance and advice to improve health and social care.

Resource Paul Workman - Chief Executive and President of The Institute of Cancer Research.

Resource Royal Marsden NHS Foundation Trust - Hospital dedicated to cancer diagnosis, treatment, research and education.

Resource The Lancet - Scientific Journal dedicated to medical research.

Read full article on BBC website
More Cancer information, news and resources